its sensitivity is limited in early relapse. Assays to distinguish donor from patient-specific alleles are not clinically available at present. Therefore, the degree to which HLA loss contributes to relapse after the PTCy haplo platform is unknown. Herein, we report the first direct evidence that genomic HLA loss may occur after haplo BMT with PTCy.
Two high-risk AML patients in first complete remission received nonmyeloablative (NMA) conditioning, which consisted of fludarabine 30 mg/m 2 intravenous (IV), days − 6 to − 2), Cy (14.5 mg/kg IV, days − 6 and − 5) and total body irradiation (200 cGy, day − 1). Both patients received a T-cell replete BM graft with a total nucleated cell (TNC) count of 2.9 × 10 7 TNC/kg for recipient 1 and 5.92 × 10 7 TNC/kg for recipient 2 followed by PTCy (50 mg/kg IV on days +3 and +4), mycophenolate mofetil and tacrolimus (Supplementary Table 1 ). 3 In the setting of 100% donor chimerism, recipient 1 developed isolated testicular relapse 8 months post transplant that was treated with surgery, radiation and prophylactic intrathecal chemotherapy. At 12 months, BM and PB studies confirmed 100% donor chimerism and remission. Systemic relapse developed at 13 months with BM revealing 63% myleoblasts and 49% recipient DNA. He underwent reinduction, followed by a second NMA haplo BMT from a different donor. At the time of publication, 1 year after second BMT, he was in remission receiving azacitidine maintenance. For recipient 2, PB and BM studies showed 100% donor chimerism and remission at 12 and 18 months post transplant. Systemic relapse developed at 22 months when the BM revealed 20% myeloblasts and 36% recipient DNA. At the time of publication, after receiving two salvage regimens, recipient 2 was in remission at day 90 after second NMA BMT from a mismatched unrelated donor.
For recipient 1, G-banded karyotype analysis at the time of systemic relapse showed a complex karyotype similar to the findings at diagnosis. SNP array was performed on the relapse sample BM and PB, and detected the presence of both patient and donor alleles. However, a clonal 38.2 Mb region of CN-LOH was present on the short arm of chromosome 6. Specifically, CN-LOH occurred in two regions of shared recipient and donor haplotype: the terminal end (4.9 Mb from terminal to p25.1) and more Figure 1a ). To confirm putative HLA loss, we performed reverse sequence-specific oligonucleotide (rSSO) hybridization and melting curve analysis of the targeted alleles. For rSSO, based on pretransplant HLA typing results ( Supplementary Table 1 ), PB samples from recipient 1 and donor 1 from pretransplantation time points were utilized to determine the informative probes for mismatches between the recipient and donor alleles at HLA-A*26, HLA B*56, HLA-C*01 and DPB1*04:01. DNA mixing experiments were performed to establish a detection threshold ( Figure 1b ). None of the probes for the patient's mismatched HLA alleles were detected near the threshold level in the PB or BM at relapse. Consistent with the above, the melting curve analysis primers designed for the recipient 1-specific HLA-A*26 detected its presence in the recipient's pretransplant PB, but not in the donor PB (Figure 1c ). HLA-A*26 was not detected in the recipient's PB collected at the time of relapse, but was detected in the BM relapse sample (Figure 1d ). Importantly, the HLA-A*26 patient-specific allele was undetectable in the HLA-DR + leukemic blasts isolated from the BM and PB (Figure 1e ).
For recipient 2, G-banded karyotype analysis at the time of relapse revealed 12 cells that displayed a normal female karyotype and 8 cells (40%) that showed male sex chromosomes. In addition to the translocations t(11;19) and dic (12;17) identified in the diagnostic sample (Figure 2a ), a new interstitial deletion on chromosome 6p was detected ( Figure 2b ). SNP array showed the presence of both donor and recipient allele populations, and confirmed a clonal interstitial deletion of 15.9 Mb on chromosome 6p that includes the HLA loci (Figure 2c ). On the basis of the pretransplant HLA-typing results, we performed the HLA-specific melting curve analysis using primers for the HLA-A*03 allele of recipient 2 ( Supplementary  Table 1 ). This allele was present in the recipient pretransplant PB, but not in the donor specimen (Figure 2d ). No HLA-A*03 DNA was detected in the CD33 + leukemic blasts at relapse (Figure 2e ).
PTCy has improved the safety of haplo BMT, leading to its increased utilization. However, little is known regarding mechanisms for relapse after this transplant approach. Although HLA loss has been documented after haplo BMT using PBSCs grafts with methotrexate and anti-thymocyte globulin, 8, 10 there have been no reports of its occurrence after haplo BMT utilizing BM grafts followed by PTCy. To our knowledge, these represent the first two cases of HLA loss after NMA haplo BMT using PTCy. Both cases were identified at the time of relapse given clinical suspicion and, in recipient 2, suggestion of genomic loss on karyotype analysis. By conducting rSSO hybridization and melting curve analysis of the targeted alleles, we were able to convincingly demonstrate the loss of the mismatched recipient HLA allele on leukemic cells. rSSO, performed in recipient 1, showed evidence of this loss in post-transplant specimens for all mismatched alleles tested. Detecting 7-14 cell equivalents compared with 1212 cell equivalents for the rSSO method, the melting curve analysis offers greater specificity and sensitivity. Importantly, the melting curve analysis showed absence of the mismatched recipient HLA haplotype on the isolated leukemic blasts in both cases. Interestingly, the cases represent distinct mechanisms of HLA loss. SNP array for recipient 1 demonstrated uniparental disomy at 6p, which is the mechanism described by the Italian BMT group. 10 However, the karyotype and SNP array for recipient 2 revealed a deletion of 6p that encompassed the mismatched HLA locus. The later represents a different, but similar, genomic mechanism and supports that the leukemic cells may lose the mismatched HLA haplotype through multiple means, all resulting in evasion of the donor immune system. 12 Deciphering the incidence of HLA loss after haplo BMT with PTCy requires further study. Currently, no standardized test to detect HLA loss relapse exists. However, our cases clearly demonstrate that loss of the mismatched HLA haplotype operates as a mechanism of AML relapse after haplo BMT irrespective of graft source, conditioning or post-transplant immune suppression. Given the increasing utilization of the haplo BMT, 1 there is an urgent need to develop a broadly applicable and sensitive methodology for detecting and monitoring HLA loss. Recognizing HLA loss may allow us to better tailor treatment. For instance, there is growing experience with haplo donor lymphocyte infusion, 13, 14 which would be ineffective in HLA loss relapse, but retains the risk of GVHD. Therefore, avoidance of this potentially toxic therapy is critical in these patients. Further, the selection of a second donor with an alternative haplotype to improve graft-versus-tumor reactivity against the resistant clone may be an effective therapeutic strategy. 8, 9 In conclusion, HLA loss should be considered in patients with AML relapsing after haplo BMT with PTCy, particularly with late relapses 8 and in patients with extramedullary disease. 15 These observations support the development of a standardized test to routinely assess for HLA loss relapse after haplo BMT.
Activation of wnt/β-catenin signaling blocks monocytemacrophage differentiation through antagonizing PU.1-targeted gene transcription Tight regulation of canonical Wnt/β-catenin signaling is critical for maintaining normal hematopoiesis and its deregulation contributes to leukemia development. 1 β-catenin, a central molecule in the canonical Wnt/β-catenin signaling pathway, acts as a nuclear transcriptional co-activator with the lymphoid enhancer factor/T-cell factor (LEF/TCF) family to stimulate transcription of various target genes. 2 The intracellular level of β-catenin is controlled by a degradation complex consisting of Apc, Gsk-3β, Axin 1 and Ck-1. 2 We found that loss of Apc leads to bone marrow failure due to exhaustion of hematopoietic stem and progenitor cells in mice. 3 A marked decrease of Mac-1 + Gr-1 + myeloid cells and rapid depletion of granulocyte-macrophage progenitors (GMPs), but not megakaryocyte-erythrocyte progenitors were observed in both Apc-null 3 and transgenic mice with expression of stabilized β-catenin. 4, 5 However, whether this decrease of myeloid cells is due to a blockage of differentiation of GMPs or the depletion of GMPs in vivo or both have not been defined.
PU.1, a member of the Ets family of DNA-binding proteins, is encoded by the Sfpi1 gene and is an important transcriptional regulator that is required for the generation of early myeloid and lymphoid progenitors. 6 The PUER cells represent an experimentally manipulable cellular model system for analyzing molecular mechanisms that underlie macrophage differentiation in vitro. The PUER cells were originally derived from mouse PU.1 −/ − myeloid progenitors with expression of a conditionally active PU.1 protein fused to the ligand binding domain of the estrogen receptor (PUER). 7 Addition of 4-hydroxy-tamoxifen (4-OHT) leads to activation of PU.1 and differentiation of PUER cells. To test whether activation of Wnt/β-catenin signaling affects macrophage differentiation induced by PU.1 in PUER cells or not, we first expressed stabilized β-catenin mutant (β-catenin-S33Y) 8 in PUER cells by retroviral vector Migr1, which co-expresses EGFP (Supplementary Figure 1a) . The expression of β-catenin-S33Y was confirmed by western blot ( Supplementary  Figure 1b) . The PUER cells were derived from the original PUER line that was established in Dr. Singh's laboratory. 7 The current cell line underwent monocyte/macrophage differentiation with a low concentration of 4-OHT. Upon 4-OHT addition, PUER protein is induced in PUER cells and the cells undergo differentiation into Mac-1 + /F4/80 + macrophages within 3-5 days ( Supplementary Figure 2) . Of interest, induction of PU.1 expression in PUER cells with expression of the stabilized β-catenin resulted in a significantly low number of Mac-1 + / F4/80 + cells (Figure 1a ). In the absence of 4-OHT, PUER cells with or without stabilized β-catenin displayed the morphology of myeloid progenitors with a large nucleus (Figure 1b ). After treatment of 4-OHT for 5 days, the vector-expressing cells increased in size with an extensive cytoplasm morphologically resembling macrophages. In contrast, the PUER cells with stabilized β-catenin had the same morphology as the cells without 4-OHT treatment (Figure 1b ). Taken together, these results suggest that stabilized β-catenin blocks PU.1-induced macrophage differentiation of PUER cells. Apc negatively regulates the Wnt/β-catenin pathway by controlling the turnover of β-catenin. 3 We next explored the consequences of knockdown of the Apc gene on macrophage differentiation in PUER cells. Inhibition of Apc by Apc shRNA 1 or 2 against Apc in PUER cells led to stabilization of β-catenin ( Supplementary  Figure 3 ). After induction of PU.1 for 3 days by 4-OHT treatment, PUER cells expressing Apc shRNA1 or 2 had a lower percentage of Mac-1 + /F4/80 + cells compared with the PUER cells expressing the control vector (Figure 1c ), indicating that activation of the Wnt/β-catenin pathway by Apc inhibition also represses PU.1-induced macrophage differentiation of PUER cells. In consistence, we found that stabilized β-catenin also blocked granulocyte-macrophage colony stimulating factor (GM-CSF)driven macrophage differentiation of mouse primary bone marrow cells (Figure 1d ).
Next, we determined whether activation of Wnt/β-catenin inhibits differentiation of human U973 cells exposed to PMA. We found that either expression of stabilized β-catenin ( Supplementary Figure 4a ) or knockdown Apc expression ( Supplementary Figures 5a and b ) significantly reduced the frequency of Mac-1 + and CD14 + cells of U937 cells after exposed to PMA ( Supplementary Figure 4b; Figures 1e and f) . Furthermore, stabilized β-catenin inhibits mRNA expression of CD14, Mac-1 and Csf1r genes induced by PMA in U937 cells, as determined by quantitative real time (qRT)-PCR ( Figure 1g ). As shown in Figure 1h , the morphological features associated with mature monocytes were observed in U937 cells expressing control vector but not β-cat-S33Y after PMA treatment for 48 h. These regulates suggest that activation of Wnt/β-catenin signaling inhibits PMA-induced monocyte/macrophage differentiation of U937 cells. Together, our studies demonstrate a negative role of β-catenin overexpression in monocyte/macrophage differentiation.
To understand the mechanism by which β-catenin inhibits PU.1-mediated monocyte differentiation, we performed microarray analysis of gene expression profiling of PUER cells with expression of stabilized β-catenin or control vector before and after 24 h induction of PU.1 expression. As shown in Supplementary Figure 6 , 505 genes were markedly upregulated whereas 390 genes were Accepted article preview online 23 May 2016; advance online publication, 17 June 2016
